Aptamer Group plc (LSE:APTA) reported a series of new contract awards worth £192,000, helping lift its FY26 order book to £1.95 million. The wins include a renewed project with a top-five global pharmaceutical company, underscoring rising industry confidence in the firm’s Optimer® technology. Aptamer’s strategy—anchored in fee-for-service engagements while developing a portfolio of high-value IP—continues to gain traction, supporting its ambitions to generate long-term revenue through licensing and royalty agreements. With sustained interest from leading pharma clients and a refreshed sales pipeline, the company expects to surpass last year’s revenue performance and progress further toward therapeutic partnerships.
Aptamer’s broader outlook remains weighed down by significant financial pressures and soft technical indicators. Even so, recent strategic wins and expanding collaborations offer pockets of optimism for future growth. High leverage and ongoing losses continue to present notable risks.
More about Aptamer Group Plc
Aptamer Group plc operates within the life sciences sector, developing advanced synthetic binders via its proprietary Optimer® platform. The company partners with pharmaceutical and biotechnology organizations to create tailored therapeutic and diagnostic solutions aimed at high-value applications.
Leave a Reply